Navigation Links
Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
Date:11/7/2007

ents' utility scores were estimated and used to calculate QALYs. To determine costs, in addition to the costs of HA, patients who responded to HA treatment were assigned costs of health care utilization attributed to patients without OA, and non-responders were assigned costs of health care resources consumed by OA patients. Cost- effectiveness was expressed as average and incremental cost per QALY.

The responder rate for patients in the HA treatment arm was approximately 83 percent, and the mean QALY gained was 0.0877 for each patient responding to treatment with HA over baseline values. When the change of QALY of the non- responders was set as zero, the HA treatment yielded a cost-utility ratio of $38,964, while that of the control group ranged from $36,077 (assuming a 75 percent response rate) to $139,648 (25 percent response rate).

The study concluded that the cost-utility ratio for EUFLEXXA(TM) is within the range needed to adopt a new technology, and that the product's wider adoption would result in greater savings to the health care system.

About EUFLEXXA(TM)

EUFLEXXA(TM) (1% sodium hyaluronate) is the first and only non-avian derived hyaluronic acid approved in the U.S. for the treatment of pain caused by knee osteoarthritis and is indicated for a three-injection treatment regimen for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (eg, acetaminophen). In a prospective, randomized, double-blind, head-to-head study versus the market leading HA therapy, significantly more patients were "pain free" and "symptom free" with EUFLEXXA(TM).(2)

The process used to manufacture EUFLEXXA(TM) produces the HA that most closely resembles the HA in healthy human synovial fluid and the most highly purified HA product available today. In addition, since it is not derived from an avian source (chicken or rooster combs), the risk of reactions related to avian proteins is eliminated.(3-8
'/>"/>

SOURCE Ferring Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 15, 2014 Sysmex America, a leader ... technology, announced today an amended distributorship agreement with ... Sysmex reagents, controls and instruments including the Sysmex ... , Sysmex XP-300™, XT-Series and XN-Series Automated Hematology ... immediately and continues until August 31, 2017.  This ...
(Date:9/15/2014)... NEW YORK , Sept. 15, 2014  Mariel ... Bone Morphogenetic Protein-7 and its application in Osteoarthritis (OA) ... of leading experts to its newly formed scientific advisory ... a strategic and scientific resource to the company as ... "We are honored to have such leading ...
(Date:9/15/2014)... Mass. , Sept. 15, 2014  Decision Resources ... armamentarium continues to expand, increasing pressure to control expenditures ... Interviewed payers emphasize that although type 2 diabetes drugs ... formularies are likely to enforce additional restrictions on expensive ... France , Germany , ...
Breaking Medicine Technology:Sysmex America, Inc. Renews LABSCO Distributorship 2Sysmex America, Inc. Renews LABSCO Distributorship 3Mariel Therapeutics Appoints World Leading Experts to Inaugural Scientific Advisory Board 2Mariel Therapeutics Appoints World Leading Experts to Inaugural Scientific Advisory Board 3Mariel Therapeutics Appoints World Leading Experts to Inaugural Scientific Advisory Board 4Interviewed Payers in the EU5 Anticipate Increasing Prescribing Constraints for Premium-Priced Type 2 Diabetes Agents 2Interviewed Payers in the EU5 Anticipate Increasing Prescribing Constraints for Premium-Priced Type 2 Diabetes Agents 3
... HOUSTON, Jan. 23, 2012  Spine Pain Management, Inc. (OTC.BB: SPIN.PK), ... pleased to update investors on recent developments.    ... The company will present and meet with investors ... The day,s event is in Las Vegas, Nevada.  The ...
... 23, 2012  VentiRx Pharmaceuticals, Inc., a biopharmaceutical company ... 8 (TLR8) agonists for the treatment of cancer, ... that VTX-2337, the Company,s lead small molecule, is ... VTX-2337 directly activates human myeloid dendritic cells (mDCs), ...
Cached Medicine Technology:Spine Pain Management, Inc. Provides Corporate Updates 2VentiRx Pharmaceuticals Publishes Preclinical Data of Novel TLR8 Agonist, VTX-2337, Supporting Its Potential as an Immunotherapeutic Approach in Cancer 2VentiRx Pharmaceuticals Publishes Preclinical Data of Novel TLR8 Agonist, VTX-2337, Supporting Its Potential as an Immunotherapeutic Approach in Cancer 3
(Date:9/16/2014)... Banish headaches forever with the newest ... device for chronic migraine relief and treatment. Cefaly was ... States. Until now, US patients would directly place their ... and wait 2-3 weeks for their device to arrive. ... and once prescription and payment is received, the Cefaly ...
(Date:9/16/2014)... BamboofloorChina.com, a famous online supplier of bamboo products, has ... bamboo panels . The firm is now offering big ... high quality items. Please note that the big sale ... , According to the company’s chief executive officer, ... visit BamboofloorChina.com before September 28. BamboofloorChina.com is offering more ...
(Date:9/15/2014)... Provo, Utah (PRWEB) September 16, 2014 ... career-focused education and corporate training, is pleased to ... the company’s ICD-10-CM and PCS comprehensive skill assessments ... studies through ICD University and Panacea’s consulting division. ... expand our offering of ICD-10 to our clients,” ...
(Date:9/15/2014)... FL (PRWEB) September 16, 2014 Aging skin ... internal reason for this is loss of collagen production. ... did when young due to this slow down. Collagen holds ... skin, collagen production should be boosted. There are several ways ... through use of stem cells (non-embryonic). , "The cost is ...
(Date:9/15/2014)... researchers at the University of Copenhagen have gained ... Parkinson,s disease. The findings have recently been published ... , The defining symptoms of Parkinson,s disease ... is currently no cure for the condition, so ... the potential to shed some light on this ...
Breaking Medicine News(10 mins):Health News:Cefaly Migraine Treatment Device Now Readily Available For Widespread Purchase in United States 2Health News:Cheap Bamboo Panels Unveiled By Famous Online Supplier BamboofloorChina.com 2Health News:Panacea Healthcare Solutions to Resell Career Step’s ICD-10-CM and PCS Assessments and Case Studies 2Health News:Panacea Healthcare Solutions to Resell Career Step’s ICD-10-CM and PCS Assessments and Case Studies 3Health News:A Superior Way to Make Skin Younger and Assure Continual Collagen Production, from Sublime Beauty® 2Health News:Researchers debunk myth about Parkinson's disease 2
... LABAs ARE SAFE AND EFFECTIVE FOR COPD , ... (LABA) to increased risk for adverse events or respiratory-related ... obstructive pulmonary disease (COPD); however, a recent article shows ... metaanalysis, researchers from Spain, Argentina, and Uruguay reviewed the ...
... research suggests that high-risk women with breast cancer who do ... for developing a second breast cancer than previously thought. ... sentinel node biopsy be considered at the time of prophylactic ... findings? , The increased risk of developing breast cancer ...
... gap, experts say , , SUNDAY, May 4 (HealthDay News) ... low knowledge of child development, including basic concepts about ... act, a new study finds. , For instance, the ... can,t tell the difference between right and wrong, and ...
... high costs of hospitalizing young children for influenza creates ... the importance of preventive flu shots for children and ... to research led by Cincinnati Childrens Hospital Medical Center ... annual meeting in Honolulu, Hawaii. , After analyzing data ...
... one-third of U.S. parents have a surprisingly low-level ... for their childs physical, social and emotional growth, ... new findings, which suggest that such false parenting ... also rob kids of much-needed cognitive stimulation, will ...
... N.C. Older adults who take drugs designed to ... incontinence, high blood pressure and allergies are more ... of daily living and to walk slower, according to ... of Medicine and colleagues. , The findings, which involve ...
Cached Medicine News:Health News:News briefs: May issue of the journal Chest 2Health News:Second breast cancer may be greater than thought for high-risk women without BRCA mutations 2Health News:One-Third of Parents Lack Facts About Child Development 2Health News:One-Third of Parents Lack Facts About Child Development 3Health News:Young children hospitalized for flu associated with higher costs and higher risk illness 2Health News:Nearly one-third of US parents don't know what to expect of infants 2Health News:Commonly used medications associated with impaired physical function in older adults 2
... color microscopy camera suitable for brightfield microscopy. ... designed to capture publication quality images. The camera ... 5 frames per second at that resolution to ... decimated to provide up to 88 frames per ...
4 megapixel zoom digicam with a 4x optical zoom, Effective pixels:4.0 million CCD:1/1.8-in. type (4.13 million total pixels), Max Image size:2272 (2,272 x 1,704 pixels), Lens:4x Zoom-Nikkor; f = 7.85...
... Brilliant digital images with advanced technology: ... high density imaging technology offers the ... to 12 million output pixels at ... enlarged image data for documentation and ...
... a new standard for high-quality digital photomicrography with 3.34 ... DP11 Digital Camera, the new DP12 incorporates many new ... - 1/1.8 inch interlace scan Exposure Time ... sec. - 8 sec. Live Image Display ...
Medicine Products: